Pure Global

A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants - Trial NCT06237335

Access comprehensive clinical trial information for NCT06237335 through Pure Global AI's free database. This Phase 1 trial is sponsored by ReCode Therapeutics and is currently Recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06237335
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06237335
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants
A Phase 1, Single-Center Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 With Single-Ascending Doses in Healthy Participants

Study Focus

Cystic Fibrosis

RCT2100

Interventional

drug

Sponsor & Location

ReCode Therapeutics

Auckland, New Zealand

Timeline & Enrollment

Phase 1

Feb 01, 2024

Aug 17, 2024

32 participants

Primary Outcome

The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

Summary

This is the first-in-human study with RCT2100 and is designed to provide safety and
 tolerability data for future clinical studies.

ICD-10 Classifications

Cystic fibrosis
Cystic fibrosis, unspecified
Cystic fibrosis with other manifestations
Cystic fibrosis with pulmonary manifestations
Cystic fibrosis with intestinal manifestations

Data Source

ClinicalTrials.gov

NCT06237335

Non-Device Trial